tert-Butyl 3-(2-ethoxy-2-oxoethyl)-8-methyl-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylate

Catalog No.: 
ACTLAB950
CAS No.: 
2177266-51-0
Molecular Formula: 
C16H25N3O4
Molecular Weight: 
323.39
tert-Butyl 3-(2-ethoxy-2-oxoethyl)-8-methyl-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg97%
250mg97%
1g97%

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 3-(2-ethoxy-2-oxoethyl)-8-methyl-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylate
IUPAC Nametert-butyl 3-(2-ethoxy-2-oxoethyl)-8-methyl-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylate
Molecular FormulaC16H25N3O4
Molecular Weight323.39
SMILESO=C(CC1=CN=C2N1CCN(C2C)C(OC(C)(C)C)=O)OCC
InChI KeyUEROASIQYOHRSQ-UHFFFAOYSA-N
Synonymtert-butyl 3-(2-ethoxy-2-oxoethyl)-8-methyl-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylate*;Imidazo[1,2-a]pyrazine-3-acetic acid, 7-[(1,1-dimethylethoxy)carbonyl]-5,6,7,8-tetrahydro-8-methyl-, ethyl ester
CAS No.2177266-51-0

Synthetic Route by SureRoute

1. ACTLAB950 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACTLAB950 route product structure diagram
    ACTLAB9502177266-51-0
Inquiry

2. ACTLAB950 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACTLAB950 route product structure diagram
    ACTLAB9502177266-51-0
Inquiry

3. ACTLAB950 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACTLAB950 route product structure diagram
    ACTLAB9502177266-51-0
Inquiry

Comments (0)